How does pretransplant 𝘐𝘋𝘏1 and 𝘐𝘋𝘏2 MRD affect posttransplant outcomes in patients with AML?

How does pretransplant 𝘐𝘋𝘏1 and 𝘐𝘋𝘏2 MRD affect posttransplant outcomes in patients with AML?

The role of pre-transplant MRD assessment in patients with AMLПодробнее

The role of pre-transplant MRD assessment in patients with AML

Pre-transplant MRD status by NGS as a prognostic tool for AML and MDSПодробнее

Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS

The prognostic impact of pre-transplant MRD-positivity in patients with AMLПодробнее

The prognostic impact of pre-transplant MRD-positivity in patients with AML

How does pre-transplant MRD affect outcome in AML?Подробнее

How does pre-transplant MRD affect outcome in AML?

How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?Подробнее

How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?

Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?Подробнее

Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?

The impact of IDH mutations on the outcomes of patients with AML & inhibitors under investigationПодробнее

The impact of IDH mutations on the outcomes of patients with AML & inhibitors under investigation

Outcomes of non-intensive chemotherapy differ for IDH1 and IDH2-mutated AMLПодробнее

Outcomes of non-intensive chemotherapy differ for IDH1 and IDH2-mutated AML

Should pre-transplant MRD be used to guide treatment in AML?Подробнее

Should pre-transplant MRD be used to guide treatment in AML?

The importance of MRD in AML prognosis and therapyПодробнее

The importance of MRD in AML prognosis and therapy

Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapyПодробнее

Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapy

The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)Подробнее

The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)

The impact of IDH mutated clones in NPM1+ AMLПодробнее

The impact of IDH mutated clones in NPM1+ AML

The efficacy of olutasidenib in patients with R/R IDH-mutant AMLПодробнее

The efficacy of olutasidenib in patients with R/R IDH-mutant AML

Haploidentical transplantation for AML with MRD at transplantationПодробнее

Haploidentical transplantation for AML with MRD at transplantation

Treating patients with Enasidenib or Ivosidenib: Managing IDH-DS & other Clinical PearlsПодробнее

Treating patients with Enasidenib or Ivosidenib: Managing IDH-DS & other Clinical Pearls

Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AMLПодробнее

Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AML

Primary and secondary resistance in AMLПодробнее

Primary and secondary resistance in AML